Kazia Shares Shoot Higher As FDA Grants Rare Pediatric Disease Designation To Brain Cancer Candidate

The United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia Therapeutics’ (NASDAQ:KZIA) lead drug Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT).

AT/RT is a rare and highly-aggressive childhood brain cancer, most common cause of cancer death in children, and outcomes in many forms of childhood brain cancer have not improved in decades.